Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MF 101

Drug Profile

MF 101

Alternative Names: Menerba; Menopause Formula 101; MF-101

Latest Information Update: 27 May 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bionovo
  • Class Flavanones
  • Mechanism of Action Selective estrogen receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Vasomotor symptoms

Most Recent Events

  • 03 Apr 2012 Bionovo voluntarily suspends further enrolment in the phase III HERBA trial for Menopausal vasomotor symptoms in USA
  • 26 Oct 2011 Phase-III clinical trials in Menopausal vasomotor symptoms in USA (PO)
  • 30 Aug 2011 Adverse events data from a phase I trial in Vasomotor symptoms released by Bionovo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top